Skip to main content
. 2014 Dec 2;9(12):e113854. doi: 10.1371/journal.pone.0113854

Figure 7. In-vivo efficacy of long-term repetitive intralesional administration of the compound drug (kB1-MGMT-LODN and the carrier) in A375P human melanoma xenografts.

Figure 7

Kaplan Meier survival curve of mice bearing A375P subcutaneous xenograft. IL treatment with either 25 ug of MGMT-kB1-LODN or with control ODN or with vehicle (5% glucose) was started once tumor volume approached 75 mm3 (on day 6 post inoculation) and treatment was repeated every 4 to 5 days for up to 55 days after tumor induction.